Why the study?
There is a lack of proton therapy-specific guidelines and limited studies on managing patients with cardiac implantable electronic devices receiving proton therapy.
Does proton therapy cause cardiac implantable electronic device (CIED) malfunctions in cancer patients?
Does proton therapy cause cardiac implantable electronic device (CIED) malfunctions in cancer patients?
Cancer patients with CIEDs receiving proton therapy require specific management protocols due to the distinct properties of proton beams and the risk of device malfunction.
Answers are grounded in this paper and cite their sources.
Proton therapy warrants CIED monitoring in cancer patients; leaves open prospective validation of risk factors and protocols.
Age is a risk factor for both cardiovascular disease and cancer, and as such radiation oncologists frequently see a number of patients with cardiac implantable electronic devices (CIEDs) receiving proton therapy (PT). CIED malfunctions induced by PT are nonnegligible and can occur in both passive scattering and pencil beam scanning modes. In the absence of an evidence-based protocol, the authors emphasise that this patient cohort should be managed differently to electron- and photon- external beam radiation therapy (EBRT) patients due to distinct properties of proton beams. Given the lack of a PT-specific guideline for managing this cohort and limited studies on this important topic; the process was initiated by evaluating all PT-related CIED malfunctions to provide a baseline for future reporting and research. In this review, different modes of PT and their interactions with a variety of CIEDs and pacing leads are discussed. Effects of PT on CIEDs were classified into a variety of hardware and software malfunctions. Apart from secondary neutrons, cumulative radiation dose, dose rate, CIED model/manufacturer, distance from CIED to proton field, and materials used in CIEDs/pacing leads were all evaluated to determine the probability of malfunctions. The importance of proton beam arrangements is highlighted in this study. Manufacturers should specify recommended dose limits for patients undergoing PT. The establishment of an international multidisciplinary team dedicated to CIED-bearing patients receiving PT may be beneficial.
No takes yet. Share an insight, caveat, or question.
Mirzaei et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: